All authors: Department of Neurology, Mayo Clinic, Rochester, MN.
Crit Care Med. 2019 Jul;47(7):970-974. doi: 10.1097/CCM.0000000000003776.
There is a paucity of data on patients with new-onset status epilepticus in patients without a prior history of epilepsy; we aimed to describe clinical characteristics and assess variables predictive of outcomes.
Retrospective cohort.
Quaternary academic medical center.
Adult patients with new-onset status epilepticus.
Retrospective review of adults with new-onset status epilepticus admitted to Mayo Clinic, Rochester MN between January 1, 1990, and December 31, 2015, was performed. Patient demographics, status epilepticus etiology, Status Epilepticus Severity Score, and status epilepticus classification per the Status Epilepticus Severity Score were recorded. Six-month mortality and functional outcomes defined as modified Rankin scale (≥3 at last follow-up was considered poor) were primary outcomes. Refractory status epilepticus was a secondary outcome.
None.
One-hundred seventy-seven patients were included. Status epilepticus was convulsive in 124 (70.1%) and nonconvulsive in 53 (29.9%); 96 cases (54.2%) were refractory status epilepticus. Mean age at onset was 63 ± 18 years; 52.5% were greater than or equal to 65 years. Etiologies were acute in 50.8%, progressive in 18.1%, remote in 19.2%, and unknown in 11.9% patients. Six-month mortality was 32.2%, and 70.1% had poor modified Rankin scale at mean follow-up 3.1 ± 3.5 years. Age greater than or equal to 65 was a significant predictor of poor functional outcome and 6-month mortality. Loss of consciousness, status epilepticus classification, or age greater than or equal to 65 did not predict progression to refractory status epilepticus. Progression to refractory status epilepticus did not impact functional outcome or mortality at last follow-up.
Poor outcomes in new-onset status epilepticus were associated with older age as well as predominantly progressive or remote symptomatic disease. Further prospective investigations assessing the course and outcomes of these patients would be useful in management and prognostication.
新诊断为癫痫持续状态且既往无癫痫病史的患者相关数据较少,本研究旨在描述其临床特征并评估预后相关的预测变量。
回顾性队列研究。
四级学术医疗中心。
新诊断为癫痫持续状态的成年患者。
回顾性分析 1990 年 1 月 1 日至 2015 年 12 月 31 日期间在明尼苏达州罗切斯特市 Mayo 诊所新诊断为癫痫持续状态的成年患者。记录患者的人口统计学资料、癫痫持续状态病因、癫痫持续状态严重程度评分(Status Epilepticus Severity Score)和癫痫持续状态分类(依据癫痫持续状态严重程度评分)。主要结局为 6 个月死亡率和功能结局(最后随访时改良 Rankin 量表评分≥3 定义为预后不良)。难治性癫痫持续状态为次要结局。
无。
共纳入 177 例患者。124 例(70.1%)为癫痫持续状态为惊厥性,53 例(29.9%)为非惊厥性;96 例(54.2%)为难治性癫痫持续状态。发病时的平均年龄为 63±18 岁;52.5%的患者年龄≥65 岁。病因急性的占 50.8%,进展性的占 18.1%,远隔性的占 19.2%,未知病因的占 11.9%。6 个月死亡率为 32.2%,平均随访 3.1±3.5 年后 70.1%的患者改良 Rankin 量表评分较差。年龄≥65 岁是功能结局不良和 6 个月死亡率的显著预测因素。意识丧失、癫痫持续状态分类或年龄≥65 岁与进展为难治性癫痫持续状态无关。进展为难治性癫痫持续状态对最后随访时的功能结局或死亡率没有影响。
新诊断为癫痫持续状态患者预后不良与年龄较大以及主要为进展性或远隔性症状性疾病相关。进一步前瞻性研究评估这些患者的病程和结局将有助于管理和预后判断。